Preclinical development of a miR-132 inhibitor for heart failure treatment

MLA

Ariana Foinquinos, et al. “Preclinical Development of a MiR-132 Inhibitor for Heart Failure Treatment.” Nature Communications, vol. 11, no. 1, Jan. 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41467-020-14349-2.

APA

Ariana Foinquinos, Sandor Batkai, Celina Genschel, Janika Viereck, Steffen Rump, Mariann Gyöngyösi, Denise Traxler, Martin Riesenhuber, Andreas Spannbauer, Dominika Lukovic, Natalie Weber, Katrin Zlabinger, Ena Hašimbegović, Johannes Winkler, Jan Fiedler, Seema Dangwal, Martin Fischer, Jeanne de la Roche, Daniel Wojciechowski, … Thomas Thum. (2020). Preclinical development of a miR-132 inhibitor for heart failure treatment. Nature Communications, 11(1), 1–10. https://doi.org/10.1038/s41467-020-14349-2

Chicago

Ariana Foinquinos, Sandor Batkai, Celina Genschel, Janika Viereck, Steffen Rump, Mariann Gyöngyösi, Denise Traxler, et al. 2020. “Preclinical Development of a MiR-132 Inhibitor for Heart Failure Treatment.” Nature Communications 11 (1): 1–10. doi:10.1038/s41467-020-14349-2.